# Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

> **NCT07695701** · PHASE4 · RECRUITING · sponsor: **Eidos Therapeutics, a BridgeBio company** · enrollment: 150 (estimated)

## Conditions studied

- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
- Amyloidosis
- Amyloid Cardiomyopathy
- Transthyretin Amyloidosis

## Interventions

- **DRUG:** Acoramidis (AG10) oral tablet

## Key facts

- **NCT ID:** NCT07695701
- **Lead sponsor:** Eidos Therapeutics, a BridgeBio company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2030-08
- **Final completion:** 2030-11
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07695701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07695701, "Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07695701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*